Featured Research

from universities, journals, and other organizations

20 years of data shows treatment technique improvement for advanced abdominal cancer

Date:
April 17, 2014
Source:
Wake Forest Baptist Medical Center
Summary:
Analysis of 20 years’ worth of patient data shows that outcomes have clearly improved for patients suffering from advanced cancer of the abdomen when treated with cytoreductive surgery with Hyperthermic IntraPeritoneal Chemotherapy, or HIPEC. Cytoreductive surgery, or debulking, is removal of part of a malignant tumor which can't be completely excised and is done to enhance chemotherapy effectiveness. HIPEC is a perfusion technique in which heated chemotherapy is administered directly into the abdomen during the surgery to kill remaining cancer cells.

Meaningful long-term survival is possible for selected patients suffering from advanced cancer of the abdomen when treated with cytoreductive surgery with Hyperthermic IntraPeritoneal Chemotherapy, or HIPEC, according to a first-of-its-size analysis by physicians at Wake Forest Baptist Medical Center.

Wake Forest Baptist has the largest reported, single-center experience with cytoreductive surgery and HIPEC, said lead author Edward A. Levine, M.D., and analysis of 20 years' worth of patient data shows that outcomes have clearly improved for patients undergoing this treatment technique.

Cytoreductive surgery, or debulking, is removal of part of a malignant tumor which can't be completely excised and is done to enhance chemotherapy effectiveness. HIPEC is a perfusion technique in which heated chemotherapy is administered directly into the abdomen during the surgery to kill remaining cancer cells.

The findings are published in the current issue of the Journal of the American College of Surgeons and were presented by Levine, professor of surgery and chief of surgical oncology service at Wake Forest Baptist, last year at the annual meeting of the Southern Surgical Association.

"Peritoneal dissemination of abdominal malignancy has a clinical course marked by bowel obstruction and death," Levine said. "It traditionally does not respond well to intravenous chemotherapy. This two-phase approach has clearly extended the lives of many of our patients."

For the study, Levine and colleagues reviewed data of 1,000 patients who underwent 1,095 HIPEC procedures over the past two decades. The average age of patients was almost 53 years and slightly more than half were female. Primary tumor sites were: appendix 472(47.2 percent), colorectal 248(24.8 percent), mesothelioma 72(7.2 percent), ovary 69(6.9 percent), gastric 46(4.6 percent), others 97(9.7 percent).

Levine said the median overall survival was 29.9 months, with a five-year survival of 32.5 percent. "The data further shows that patients with advanced abdominal cancer should no longer be approached with therapeutic nihilism," he said. "Long-term survival is clearly possible for selected patients treated with HIPEC."


Story Source:

The above story is based on materials provided by Wake Forest Baptist Medical Center. Note: Materials may be edited for content and length.


Journal Reference:

  1. Edward A. Levine, John H. Stewart, Perry Shen, Gregory B. Russell, Brian L. Loggie, Konstantinos I. Votanopoulos. Intraperitoneal Chemotherapy for Peritoneal Surface Malignancy: Experience with 1,000 Patients. Journal of the American College of Surgeons, 2014; 218 (4): 573 DOI: 10.1016/j.jamcollsurg.2013.12.013

Cite This Page:

Wake Forest Baptist Medical Center. "20 years of data shows treatment technique improvement for advanced abdominal cancer." ScienceDaily. ScienceDaily, 17 April 2014. <www.sciencedaily.com/releases/2014/04/140417124153.htm>.
Wake Forest Baptist Medical Center. (2014, April 17). 20 years of data shows treatment technique improvement for advanced abdominal cancer. ScienceDaily. Retrieved September 16, 2014 from www.sciencedaily.com/releases/2014/04/140417124153.htm
Wake Forest Baptist Medical Center. "20 years of data shows treatment technique improvement for advanced abdominal cancer." ScienceDaily. www.sciencedaily.com/releases/2014/04/140417124153.htm (accessed September 16, 2014).

Share This



More Health & Medicine News

Tuesday, September 16, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

EU Ministers and Experts Meet to Discuss Ebola Reponse

EU Ministers and Experts Meet to Discuss Ebola Reponse

AFP (Sep. 15, 2014) The European Commission met on Monday to coordinate aid that the EU can offer to African countries affected by the Ebola outbreak. Duration: 00:58 Video provided by AFP
Powered by NewsLook.com
Despite The Risks, Antibiotics Still Overprescribed For Kids

Despite The Risks, Antibiotics Still Overprescribed For Kids

Newsy (Sep. 15, 2014) A new study finds children are prescribed antibiotics twice as often as is necessary. Video provided by Newsy
Powered by NewsLook.com
FDA Eyes Skin Shocks Used at Mass. School

FDA Eyes Skin Shocks Used at Mass. School

AP (Sep. 15, 2014) The FDA is considering whether to ban devices used by the Judge Rotenberg Educational Center in Canton, Massachusetts, the only place in the country known to use electrical skin shocks as aversive conditioning for aggressive patients. (Sept. 15) Video provided by AP
Powered by NewsLook.com
Respiratory Virus Spreads To Northeast, Now In 21 States

Respiratory Virus Spreads To Northeast, Now In 21 States

Newsy (Sep. 14, 2014) The respiratory virus Enterovirus D68, which targets children, has spread from the Midwest to 21 states. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins